News | August 15, 2024
Evonik expands its formulation capabilities for lipid nanoparticles
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The inspection was concluded with zero observations
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Subscribe To Our Newsletter & Stay Updated
